Navidea Biopharmaceuticals Inc (NYSE American:NAVB)

0.359
Delayed Data
As of Feb 23
 +0.014 / +4.06%
Today’s Change
0.31
Today|||52-Week Range
0.85
+0.14%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$58.3M

Company Description

Navidea Biopharmaceuticals, Inc. engages in the development and commercialization of precision immunodiagnostic agents and immunotherapeutic. It is developing multiple precision-targeted products based on their manocept platform to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making, targeted treatment and, ultimately, patient care. The company operates through the following segments: Diagnostics, Therapeutics, and Corporate. The company was founded in 1983 and is headquartered in Dublin, OH.

Contact Information

Navidea Biopharmaceuticals, Inc.
5600 Blazer Parkway
Dublin Ohio 43017-1367
P:(614) 793-7500
Investor Relations:

Employees

Shareholders

Mutual fund holders4.54%
Individual stakeholders14.47%
Other institutional12.96%

Top Executives

Mike M. GoldbergPresident, Chief Executive Officer & Director
Jed Andrew LatkinCFO, COO, Secretary & Treasurer
Frederick O. CopeChief Scientific Officer & Senior Vice President
William J. ReganChief Compliance Officer & SVP-Global Regulatory